A formula (I): X-A-Ligante-B-Z(I) is provided, in which: (1) A and B are identical or different and independent: (a) a polypeptide, including a Sacol0029 polypeptide, as shown in any sequence described in Table 24 (Sections ID Nos.5 and 1). Paragraphs 21 to 131,1. Sacol0264 polypeptide (ID No: 185)；According to a Sacol 0442 polypeptide described in any sequence described in FIG.22D (Sections 29 and 82-92),1. Sacol 0718 polypeptide (Section 186)；A sack-like polypeptide 0720 is displayed in any sequence described by FIGS Ibid., sect. 23I-J (paras. 11 and 109-120).1. A Polipe e ptido Sacol 1353 (Section ID No: 187)；A Polipeiptido Sacol 1416 (Section ID No: 188),1. Sacol 1611 polypeptide (Section 189)；5. A Sacol 1867 polypeptide, as shown in any sequence described in FIG.25D (ID No. 152-164)；1. Sacol 1912 polypeptide (Section 43)；1. Polypeptide of the Board in 1944 (CID 190)；1. Sacol 2144 polypeptide (ID No: 191)；1. Sacol 2365 polypeptide (Section 192)；1. A polp_ ptido sacol 2385 (Sec. ID No. 50) or A polp_ ptido sacol 2599 (Sec. ID No. 193)；According to the gene naming of Staphylococcus aureus gene (SACOL) shown in NCBI NC_U002951.2 reference sequence； (b) a polypeptide encoded by an OPEC gene and a polypeptide encoded by a gene；(c) Polypeptides, including at least 13 consecutive (a) or (b) amino acid immune fragments；(d) A polypeptide containing at least 60% of the amino acid sequence, identical to (a) to (c) any polypeptide sequence；O(e) a polypeptide consisting of at least 13 consecutive amino acids (A) to (C)；(2) Ligating agent is a series of amino acids, including at least one amino acid or omission； (3) x is a series of amino acids with omission or at least one amino acid； and (4) Z is a series of amino acids with omission or at least one amino acid. In addition, various materials and toolkits for merging and using these mergers, combinations and toolkits are provided.Se proporciona un constructo de fusión de fórmula (I): X-A-ligante-B-Z (I) donde : (1) A y B son
